These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 16450753)

  • 1. On the complexity of the pulmonary microbiology in cystic fibrosis: thoughts of a clinician.
    Katznelson D
    Isr Med Assoc J; 2006 Jan; 8(1):49-52. PubMed ID: 16450753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
    Murray TS; Egan M; Kazmierczak BI
    Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiology: a resistance switch.
    O'Toole GA
    Nature; 2002 Apr; 416(6882):695-6. PubMed ID: 11961541
    [No Abstract]   [Full Text] [Related]  

  • 4. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.
    Hassett DJ; Sutton MD; Schurr MJ; Herr AB; Caldwell CC; Matu JO
    Trends Microbiol; 2009 Mar; 17(3):130-8. PubMed ID: 19231190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaerobic culture conditions favor biofilm-like phenotypes in Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
    O'May CY; Reid DW; Kirov SM
    FEMS Immunol Med Microbiol; 2006 Dec; 48(3):373-80. PubMed ID: 17052266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
    Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms.
    Alkawash MA; Soothill JS; Schiller NL
    APMIS; 2006 Feb; 114(2):131-8. PubMed ID: 16519750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA; Mauldin PD; Steed LL
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk assessment of Pseudomonas aeruginosa in water.
    Mena KD; Gerba CP
    Rev Environ Contam Toxicol; 2009; 201():71-115. PubMed ID: 19484589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxygen, cyanide and energy generation in the cystic fibrosis pathogen Pseudomonas aeruginosa.
    Williams HD; Zlosnik JE; Ryall B
    Adv Microb Physiol; 2007; 52():1-71. PubMed ID: 17027370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
    Tré-Hardy M; Vanderbist F; Traore H; Devleeschouwer MJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):329-36. PubMed ID: 18280117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression characteristics of a cystic fibrosis epidemic strain of Pseudomonas aeruginosa during biofilm and planktonic growth.
    Manos J; Arthur J; Rose B; Bell S; Tingpej P; Hu H; Webb J; Kjelleberg S; Gorrell MD; Bye P; Harbour C
    FEMS Microbiol Lett; 2009 Mar; 292(1):107-14. PubMed ID: 19222585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chelated iron sources are inhibitors of Pseudomonas aeruginosa biofilms and distribute efficiently in an in vitro model of drug delivery to the human lung.
    Musk DJ; Hergenrother PJ
    J Appl Microbiol; 2008 Aug; 105(2):380-8. PubMed ID: 18284482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
    Nguyen D; Emond MJ; Mayer-Hamblett N; Saiman L; Marshall BC; Burns JL
    Pediatr Pulmonol; 2007 Jun; 42(6):533-41. PubMed ID: 17469154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
    Bradbury R; Champion A; Reid DW
    Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron acquisition by Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis.
    Lamont IL; Konings AF; Reid DW
    Biometals; 2009 Feb; 22(1):53-60. PubMed ID: 19130260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in biofilm development and antibiotic susceptibility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures.
    García-Castillo M; Morosini MI; Valverde A; Almaraz F; Baquero F; Cantón R; del Campo R
    J Antimicrob Chemother; 2007 Feb; 59(2):301-4. PubMed ID: 17142818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis.
    Hogardt M; Hoboth C; Schmoldt S; Henke C; Bader L; Heesemann J
    J Infect Dis; 2007 Jan; 195(1):70-80. PubMed ID: 17152010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.